NCT06779851 2026-04-22
SUMMIT-1
Bright Peak Therapeutics Inc
Phase 1 Terminated
Clinical Trials
350 trialsNCT07387068 2026-04-22
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Genmab
Phase 1 Recruiting
NCT06480552 2026-04-21
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Recruiting
NCT06532565 2026-04-21
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
Gilead Sciences
Phase 1 Recruiting
NCT07346846 2026-04-21
A Study of BGM-2121 in Patients With Advanced Solid Tumors
BioGate Precision Medicine Corp.
Phase 1 Recruiting
NCT07539285 2026-04-20
A Study of HDM2024 in Participants With Advanced Solid Tumors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT03317743 2026-04-17
Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors
Idience Co., Ltd.
Phase 1 Completed
NCT06596473 2026-04-15
A Study of BG-C477 in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT05879627 2026-04-13
To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors
Bio-Thera Solutions
Phase 1 Terminated
NCT07524348 2026-04-13
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
Samsung Bioepis Co., Ltd.
Phase 1 Recruiting
NCT06832982 2026-04-09
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
Shanghai Pushi Medical Science Co. Ltd
Phase 1 Recruiting
NCT06773091 2026-04-06
NKSOLID
Shanghai NK Cell Technology Co., LTD
Phase 1 Recruiting
NCT05109975 2026-03-30
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
Debiopharm International SA
Phase 1 Active not recruiting
NCT06770569 2026-03-30
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
Phase 1 Recruiting
NCT07482319 2026-03-23
A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid Tumors
Beijing Geekgene Technology Co., LTD
Phase 1 Not yet recruiting
NCT06804824 2026-03-18
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Phase 1 Recruiting
NCT05781048 2026-03-10
A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Active not recruiting
NCT07446816 2026-03-03
A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 1 Recruiting
NCT06715124 2026-03-02
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Quanta Therapeutics
Phase 1 Active not recruiting
NCT05914376 2026-02-27
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors
Hangzhou Converd Co., Ltd.
Phase 1 Active not recruiting
NCT07413328 2026-02-27
HWS116 Monotherapy in Patients With Advanced Solid Tumors
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Phase 1 Not yet recruiting
NCT05800964 2026-02-17
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
Amgen
Phase 1 Completed
NCT05067283 2026-02-12
KANDLELIT-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT05620017 2026-02-09
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
Bio-Thera Solutions
Phase 1 Recruiting
NCT06331559 2026-02-09
Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT07215637 2026-02-02
Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
Chong Kun Dang Pharmaceutical
Phase 1 Recruiting
NCT07377591 2026-01-30
A Study of HDM2006 in Patients With Advanced Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06792552 2026-01-29
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NextCure, Inc.
Phase 1 Recruiting
NCT07042100 2026-01-22
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
Sun Pharma Advanced Research Company Limited
Phase 1 Recruiting
NCT05868915 2026-01-21
HV-101 for Patients With Advanced Solid Tumors
Hervor Therapeutics
Phase 1 Terminated
NCT07356453 2026-01-21
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
FoRx Therapeutics AG
Phase 1 Recruiting
NCT06927570 2026-01-16
A Study of HS-20122 in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT07186452 2026-01-16
Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT07231458 2026-01-16
A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies
Abalos Therapeutics GmbH
Phase 1 Recruiting
NCT06990464 2026-01-08
A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
Shanghai Institute Of Biological Products
Phase 1 Recruiting
NCT05378737 2026-01-06
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection
Bio-Thera Solutions
Phase 1 Completed
NCT05864573 2026-01-05
Study of ZGGS15 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1 Completed
NCT07077434 2026-01-05
A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
NCT07252414 2026-01-05
GenSci143 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06384352 2026-01-02
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1 Recruiting
NCT07310134 2026-01-02
Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors
Nanjing Zenshine Pharmaceuticals
Phase 1 Recruiting
NCT06882135 2025-12-29
HW071021 Monotherapy in Patients With Advanced Solid Tumors
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Phase 1 Recruiting
NCT07230977 2025-12-24
GenSci139 in Patients With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT07251166 2025-12-24
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05240898 2025-12-18
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT05287399 2025-12-18
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors
Ascletis Pharma Inc
Phase 1 Completed
NCT07266285 2025-12-17
BTM-3566 in Advanced Solid Tumors
Bantam Pharmaceuticals
Phase 1 Recruiting
NCT07285395 2025-12-16
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
The Affiliated Hospital of Xuzhou Medical University
Phase 1 Recruiting
NCT07275853 2025-12-10
Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors
TCRx Therapeutics Co.Ltd
Phase 1 Not yet recruiting
NCT05105971 2025-12-08
Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China
Bio-Thera Solutions
Phase 1 Completed